A long-lasting formulation of an antiviral drug greatly reduced people’s risk of a symptomatic flu infection in a trial, and should even be effective against new strains

The Cambridge biotech believes packaging the two immunizations together will lead to higher uptake of COVID vaccines.

The biotechnology company’s messenger RNA flu vaccine candidate showed positive results in a late-stage trial.